在接受放射治疗的肺癌患者中,超极化XENON-129磁共振成像用于研究辐射反应和毒性
The goal of this clinical research study is to learn if novel type of imaging scan called HP 129Xe MRI can help doctors identify and predict common side effects of radiation therapy. Rather than contrast-enhanced MRIs, the tracer (129Xe) will be inhaled rather than injected.
The 129Xe tracer has not been FDA approved. Its use in this study is investigational.
研究概览
详细说明
Primary Objectives:
To assess the association between imaging features on longitudinal HP 129Xe MRI and the development and severity of radiation pneumonitis resulting from radiation therapy for non-small cell lung cancer.
To determine if HP 129Xe MRI features, in conjunction with a given patient's radiation treatment plan, can predict radiation pneumonitis development and severity.
Secondary Objectives:
Optimize HP 129Xe MRI acquisition techniques.
To determine if HP 129Xe MRI can pre-emptively detect radiation pneumonitis prior to symptom presentation.
Compare changes in HP 129Xe MRI metrics to CT-based ventilation metrics over the course of radiation therapy.
To identify pulmonary regions more susceptible to radiation damage.
To develop alternative radiation treatment plans, based on HP 129Xe MRI features of lung function, that may prevent radiation pneumonitis development and compare to standard-of-care treatment plans.
研究类型
注册 (估计的)
联系人和位置
学习联系方式
- 姓名:Joshua Niedzielski, PHD
- 电话号码:(713) 745-8946
- 邮箱:jsniedzielski@mdanderson.org
学习地点
-
-
Texas
-
Houston、Texas、美国、77030
- 招聘中
- The University of Texas M. D. Anderson Cancer Center
-
接触:
- Joshua Niedzielski, PHD
- 电话号码:713-745-8946
- 邮箱:jsniedzielski@mdanderson.org
-
首席研究员:
- Joshua Niedzielski, PHD
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
MD Anderson Cancer Center Participants
描述
Inclusion Criteria:
-
Healthy control cohort:
- Able to consistently hold breath for 10-12 seconds
- No history of any pulmonary disorders (i.e., asthma, COPD, lung cancer, etc.)
- Able to undergo MRI examination
- At least 18 years of age
-
Lung cancer patient cohort:
- Biopsy proven diagnosis of lung cancer
- Receiving photon- or proton-based external beam radiotherapy as a part of treatment
- Able to undergo MRI examination
- Will receive follow-up at University of Texas MD Anderson Cancer Center (UTMDACC)
- Able to consistently hold breath for 10-12 seconds
- Women and men with child-bearing potential agree to use adequate contraception prior to study entry and during the duration of study participation.
- Able to understand and willing to sign a written informed consent document
- At least 18 years of age
The effects of HP 129Xe MRI on the developing human fetus are unknown. For this reason and because radiotherapy is known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. (Refer to Pregnancy Assessment Policy MD Anderson Institutional Policy # CLN1114). This includes all female patients, between the onset of menses (as early as 8 years of age) and 55 years unless the patient presents with an applicable exclusionary factor which may be one of the following:
- Postmenopausal (no menses in greater than or equal to 12 consecutive months).
- History of hysterectomy or bilateral salpingo-oophorectomy.
- Ovarian failure (Follicle Stimulating Hormone and Estradiol in menopausal range, who have received Whole Pelvic Radiation Therapy).
- History of bilateral tubal ligation or another surgical sterilization procedure.
- Approved methods of birth control are as follows: Hormonal contraception (i.e. birth control pills, injection, implant, transdermal patch, vaginal ring), Intrauterine device (IUD), Tubal Ligation or hysterectomy, Subject/Partner post vasectomy, Implantable or injectable contraceptives, and condoms plus spermicide. Not engaging in sexual activity for the total duration of the trial and the drug washout period is an acceptable practice; however periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of birth control. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Additionally, if female partners of male study participants become pregnant during study participation, the treating physician should be informed immediately.
- Ability to understand and the willingness to sign a written informed consent document.
Exclusion Criteria:
- Patients unable to follow up at MD Anderson for routine clinical care
- Inability or unwillingness to give informed consent
- Relapsed disease or life expectancy less than 6 months at time of enrollment
- Severe claustrophobia precluding MRI imaging active pulmonary infection
- Pregnant women
- Under 18 years of age
学习计划
研究是如何设计的?
设计细节
- 观测模型:CASE_CONTROL
- 时间观点:PROSPECTIVE
队列和干预
团体/队列 |
干预/治疗 |
|---|---|
|
Arm A: High-Risk RP Patients
|
Gas delivery will be from a Tedlar bag |
|
Arm B: Low-Risk RP Patients
|
Gas delivery will be from a Tedlar bag |
|
Arm C: Healthy Volunteers (Negative Control)
|
Gas delivery will be from a Tedlar bag |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Safety and Adverse Events (AEs)
大体时间:Through study completion; an average of 1 year
|
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0 |
Through study completion; an average of 1 year
|
合作者和调查者
调查人员
- 首席研究员:Joshua Niedzielski、M.D. Anderson Cancer Center
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.